HIV Infections
Conditions
Keywords
Efavirenz, HIV Infections
Brief summary
Prospective, Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) Plus Tenofovir Disoproxil Fumarate (TDF) and Lamivudine in a Fixed-Dose Combination Tablet (Combo) for Patients Receiving Co-Formulated TDF, Emtricitabine and Efavirenz (Atripla) with Viral Suppression in Taiwan
Detailed description
Efavirenz (EFV) is the most widely used non-nucleoside reverse transcriptase inhibitor (NNRTI). The recommended dose of EFV is 600 mg daily; however, a phase II study showed no significant difference in viral suppression rates across the different EFV groups (200 mg, 400 mg, and 600 mg) at 24 weeks. The week 96 analysis of ENCORE 1 study confirmed the durable virological non-inferiority of EFV 400 mg to the standard 600 mg dose when given as initial therapy with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). Fewer EFV-related adverse events (AEs) and fewer treatment discontinuations were also observed in the reduced dose group. The efficacy and safety findings provide robust evidence to redefine the EFV dose for HIV treatment.
Interventions
DRUG3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg)
All eligible subjects will receive 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg) once daily for 24 weeks orally on empty stomach before bedtime. If the event of toxicity or tolerability issues requires a change from study drug, switching to the best available treatment will be recommended.
Sponsors
Yu-Jay Corp.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Single-arm, open-label
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who are receiving co-formulated TDF/ FTC/ EFV (600 mg) and have achieved an undetectable plasma viral load (\<50 copies/mL) for 6 months or longer at screening visit. * Having C12 EFV of 1 mg/L or greater at screening. * (C12 EFV will be determined by using blood sample collected 12 ± 1 hour after previous dosing of co-formulated TDF/ FTC/ EFV (600 mg). * No known treatment failure to regimens containing TDF, 3TC or FTC, plus EFV. * Infected with HIV harboring no known resistance-associated mutations to EFV, TDF, 3TC or FTC. * No known allergies to EFV, TDF, 3TC or FTC. * Aged ≧20 years. * Calculated creatinine clearance (ClCr) ≥ 50 mL/min (Cockcroft-Gault formula). * Provision of written informed consent.
Exclusion criteria
* The following laboratory values: * Absolute neutrophil count (ANC) \<500 cells/μL * Hemoglobin \<7.0 g/dL * Platelet count \<50,000 cells/μL * Serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels \>5x upper limit of normal (ULN) * Pregnant women or nursing mothers. * Active opportunistic or malignant disease not under adequate control. * Use of immunomodulators within 30 days prior to screening visit. * Use any of the prohibited medications: bepridil, astemizole, terfenadine, dihydroergotamine, ergometrine, ergotamine, systemic cytotoxic chemotherapy, amodiaquine, pimozide, midazolam, triazolam, cisapride、St John's Wort、 Elbasvir/Grazoprevir and Simeprevir.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| C12 EFV concentration | Week 4 | The proportion of subjects achieving C12 EFV concentration \>1.0 mg/L at Week 4. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| HIV-1 RNA load | Week 12 | The proportion of subjects with undetectable plasma HIV-1 RNA load (\<50 copies/mL) at Week 12 |
| EFV concentration | Week 4 | The mean changes from baseline in C12 EFV concentration at Week 4. |
| CD4+ T cell count | Week 12 | The mean changes from baseline in CD4+ T cell count at Week 12. |
Countries
Taiwan
Outcome results
None listed